SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [see comment; erratum appears in N Engl J Med. 2003;349:1880]. N Engl J Med. 2003; 349: 859866.
  • 2
    International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 21712177.
  • 3
    Bajorin DF. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol. 2001; 19(18 suppl): 17S20S.
  • 4
    Sternberg CN, Parmar MK. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol. 2001; 19(18 suppl): 21S26S.
  • 5
    Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009; 27: 40624067.
  • 6
    Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol. 2010; 57: 728729.
  • 7
    Siefker-Radtke AO, Kamat AM, Williams DL, et al. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: final results from the M. D. Anderson Cancer Center [abstract]. J Clin Oncol. 2009; 27( 15S). Abstract 5071.
  • 8
    Plunkett W, Ghandi, V. Nucleoside analogs: cellular pharmacology, mechanisms of action and strategies for combination therapy. In: Cheson BKM, Plunkett W, eds. Nucleoside Analogs in Cancer Therapy. New York: Marcel Dekker, Inc.; 1997: 135.
  • 9
    Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer. 2001; 92: 194199.
  • 10
    Pagliaro LC, Millikan RE, Tu SM, et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002; 20: 29652970.
  • 11
    Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 40054013.
  • 12
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 13
    Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 41044109.
  • 14
    Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004; 171( 2 pt 1): 570574.